eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
4/2009
vol. 13
 
Share:
Share:
abstract:
Review paper

Capecitabine in palliative chemotherapy of colorectal cancer – efficacy and toxicity

Rafał Stec
,
Lubomir Bodnar
,
Cezary Szczylik

Współczesna Onkologia (2009) vol. 13; 4 (167-176)
Online publish date: 2009/09/15
View full text Get citation
 
Capecitabine is an oral carbamate of fluoropyrimidine, precursor of 5-fluorouracil. Activation of capecitabine proceeds by way of three steps. The final step of conversion to 5-fluorouracil is catalyzed by thymidine phosphorylase, which is four times more active in tumour cells than in healthy tissue. In the treatment of colorectal cancer are used the following schemas of palliative chemotherapy containing capecitabine: monotherapy of capecitabine, XELIRI (capecitabine + irinotecan), XELOX (capecitabine + oxaliplatin), CAPLRI/Bev (bevacizumab + capecitabine/irinotecan), CAPOX/Bev (bevacizumab + capecitabine/ /oxaliplatin). In the presented clinical trials, the effectiveness of an oral capecitabine in combination with irinotecan or oxaliplatin is comparable to intravenous schemas FOLFIRI and FOLFOX, with a slightly better safety profile. In conclusion, an oral capecitabine in monotherapy or combination is an interesting alternative to intravenous chemotherapy and could be considered in the treatment of metastatic colorectal cancer.
keywords:

colorectal cancer, palliative chemotherapy, capecitabine, oxaliplatin, irinotecan

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.